← All publications

Academic research

ANR / ERA4Health: 2027 call on nanotechnologies for diagnosis

Fund transnational translational research projects that apply nanotechnologies to the diagnosis of non-communicable diseases.

Status
Upcoming
Next deadline
19 January 2027 (pre-proposals, indicative)
Operator
ANR / ERA4Health

At a glance

Programme
ERA4Health partnership, 2027 NanoDiagNCD call
Territory
18 participating countries, including France; participation of Greece and Portugal not yet confirmed
Beneficiaries
Transnational consortia of 3 to 5 partners; eligibility of French companies to be confirmed in the call specifications
Type of aid
Funding for transnational research projects; ANR terms to be confirmed in the call specifications
Amount / rate
Not disclosed in the pre-announcement; projects funded over 36 months
Availability
Pre-announcement; launch planned for 17 November 2026, two-stage submission

Information up to date as of 6 November 2026, valid until 19 January 2027. Scheme conditions change: check with the funding body or ask us for confirmation.

ANR (the French National Research Agency) announces the launch, on 17 November 2026, of a transnational call of the ERA4Health partnership dedicated to nanotechnologies for diagnostic and theranostic tools for non-communicable diseases (NanoDiagNCD call). As of 6 November 2026, this is only a pre-announcement, indicative and subject to change: pre-proposals are expected by 19 January 2027, but the amounts, eligible costs and rules applicable to French partners have yet to be published.

Which projects are funded?

The call supports translational research projects that develop applications of nanotechnologies, alone or combined with key enabling technologies (KETs), to advance diagnostic and theranostic tools for non-communicable diseases.

Proposals focus on the development and/or validation of tools based on sound scientific evidence. Their results must make it possible to optimise the continuum of care, which includes in particular:

  • prevention;
  • early detection of disease;
  • disease monitoring;
  • guiding therapeutic choice;
  • assessment of adverse effects and/or the benefit/risk ratio.

Excluded are:

  • projects in which nanotechnology is not central;
  • the discovery of new biomarkers (the development of known biomarkers remains possible, for example to improve the performance of existing tests, integrate several biomarkers on a single platform or adapt their use to a new application);
  • infectious diseases, except chronic diseases resulting from a previous infection.

Who can apply?

Only transnational projects are funded. Partners fall into one of the following categories, and their eligibility may vary according to national or regional rules:

  • A: academic research;
  • B: clinical research (clinical and public health sector, in the English version);
  • C: companies;
  • D: operational stakeholders.

Each consortium must bring together partners requesting funding in at least two of the three categories A, B and C, and it is important to include category D partners. The composition must comply with the following rules:

  • three to five eligible partners, from at least three countries participating in the call;
  • among them, at least two eligible partners from two different EU Member States or countries associated with Horizon Europe, participating in the call;
  • up to six or seven eligible partners if the consortium includes one or two partners from Lithuania, Slovakia or Taiwan;
  • no more than two eligible partners from the same country;
  • at most two collaborators taking part with their own funds, without requesting funding.

The participating countries are Belgium, Egypt, Spain, France (ANR), Greece, Hungary, Israel, Italy, Latvia, Lithuania, Norway, the Netherlands, Poland, Portugal, Romania, Slovakia, Taiwan and Türkiye. The participation of the Greek and Portuguese funders is not yet confirmed. Thanks to the Access2Partnerships (A2P) scheme of the Maltese agency Xjenza Malta, researchers based in Malta can also take part as self-funded partners, with possible support if the project is selected and subject to an accepted national application.

Companies are among the planned categories, but the pre-announcement does not specify the conditions under which ANR funds a French company: this point is to be confirmed in the call specifications.

Which costs are eligible?

  • Each partner is funded by its national or regional body, hence by ANR for French partners.
  • Eligible costs and financial rules vary from one funder to another.
  • The list of eligible costs on the ANR side has not been published: to be confirmed in the call specifications.

How much funding is available?

The pre-announcement gives no amount, rate or ceiling. It indicates a funding period of 36 months. The amount available to a French partner is to be confirmed in the call specifications.

Main selection criteria

Selection takes place in two stages, pre-proposals then full proposals, and the evaluation of full proposals includes a right-to-reply phase. The evaluation grid has not yet been published. The pre-announcement does, however, set requirements that projects will have to meet:

  • define and validate performance thresholds against existing diagnostic approaches, to demonstrate added value on at least one criterion: sensitivity, specificity, accessibility, cost, patient comfort, invasiveness or safety;
  • anticipate from the outset the conditions for clinical translation and adoption: scale-up, manufacturing, standardisation, accessibility, cost-effectiveness, regulatory requirements, interoperability, integration into different healthcare systems;
  • for a theranostic tool, apply the "diagnostic-first" principle, in which diagnosis guides the therapeutic choice;
  • present a consortium balanced between countries, with sufficient critical mass and demonstrating the added value of working together.

Points to watch

  • The content of the pre-announcement is indicative and may change; the English version specifies that it is not legally binding.
  • The timetable is tight: nine weeks separate the planned launch (17 November 2026) from the pre-proposal deadline (19 January 2027, at 12:00 according to the English version).
  • The deadline for full proposals has not yet been published.
  • The eligibility of a French company for ANR funding is not guaranteed: it depends on national rules, yet to be published.
  • A project in which nanotechnology is not central, or which aims to discover new biomarkers, is excluded.

The CHOICE view

This call is aimed at teams that already have a nanotechnology applied to diagnosis and can compare it, with figures to back it up, with existing methods. For a French company, the first thing to secure is its eligibility for ANR funding, as soon as the call text is published, before investing time in putting the application together. Given the short submission window, the consortium and the scientific positioning are worth working on now, without finalising a budget until the national rules are known.

How to prepare your project

  • Bring together three to five partners in at least three participating countries, checking that each comes under a funder committed to the call.
  • Cover at least two of the categories academic research, clinical research and companies, and involve operational stakeholders.
  • Choose the reference diagnostics and the performance thresholds to be exceeded.
  • Document the conditions for adoption: manufacturing, standardisation, regulatory aspects, interoperability.
  • Attend the information webinar on 19 November 2026.
  • Check the ANR rules (eligibility, costs, amounts) as soon as the call text is published.

Official sources

The conditions of a scheme can change. This fact sheet was checked on the date shown; only the call specifications, the official texts and the funding body's decision are authoritative.

How CHOICE works on this kind of application

Finding the right scheme is only one step. What matters happens before: clarifying the project, gathering the expected evidence, bringing in the right partners and sequencing commitments.